Arnous Maha M, Al Saidan Aseel A, Al Dalbhi Sultan, Balghith Mohammed A, Al Tahan Talal M, Al Sayed Khalid A
Department of Family Medicine, Security Forces Hospital, Jouf University, Sakaka, Aljouf 74311, Saudi Arabia.
Family & Community Medicine, College of Medicine, Jouf University, Sakaka, Aljouf 74311, Saudi Arabia.
J Family Med Prim Care. 2022 Jul;11(7):3880-3884. doi: 10.4103/jfmpc.jfmpc_577_21. Epub 2022 Jul 22.
Many studies have provided evidence for an increased risk of atrial fibrillation among diabetic patients as compared to the nondiabetic population. It is also well known that diabetes predisposes a person to an increased risk of diabetic nephropathy. A few reviews and studies have hinted towards an increased risk of atrial fibrillation among diabetic nephropathy patients; however, there is no concrete evidence at present.
To conduct a meta-analysis to explore if there is an association between diabetic nephropathy and atrial fibrillation.
The available literature was searched for relevant studies from the period of January 1995 to November 2020. The following quality assessment criteria were considered for study shortlisting: clearly defined comparison groups, same outcome measured in both comparison groups, known confounders addressed, and a sufficiently long and complete (more than 80%) follow-up of patients. Two independent reviewers searched the databases, formed their search strategies, and finalized the studies. The data were analyzed to obtain a summary odds ratio along with a forest plot by Cochrane's RevMan 5.3.
Only four studies were found to meet the inclusion criterion for this meta-analysis (total number of study participants: 307330, diabetic nephropathy patients: 22855). Of these, two were retrospective cross-sectional studies, one was a prospective cohort study, and one was a case-control study. Three studies had provided the odds ratio as the measure of effect (two retrospective cross-sectional studies and one case-control study), with the one cohort study reporting the hazards ratio as the measure of effect. Therefore, the meta-analysis was done excluding the cohort study. The summary odds ratio in the present study was 1.32 (0.80-2.18), which was not statistically significant. Due to large heterogeneity among the included studies and their small sample sizes, it was found that the summary estimate shifted towards the null value.
The present meta-analysis found no significant association between atrial fibrillation and diabetic nephropathy. However, more studies with large sample sizes are required to strengthen the evidence for an association.
许多研究已提供证据表明,与非糖尿病人群相比,糖尿病患者发生心房颤动的风险增加。众所周知,糖尿病会使一个人患糖尿病肾病的风险增加。一些综述和研究已暗示糖尿病肾病患者发生心房颤动的风险增加;然而,目前尚无确凿证据。
进行一项荟萃分析,以探讨糖尿病肾病与心房颤动之间是否存在关联。
检索1995年1月至2020年11月期间的相关研究文献。研究入围的质量评估标准如下:明确界定的对照组、在两个对照组中测量相同的结局、考虑已知的混杂因素以及对患者进行足够长且完整(超过80%)的随访。两名独立的审阅者检索数据库,制定检索策略并确定研究。通过Cochrane的RevMan 5.3对数据进行分析,以获得汇总比值比及森林图。
仅发现四项研究符合本荟萃分析的纳入标准(研究参与者总数:307330,糖尿病肾病患者:22855)。其中,两项为回顾性横断面研究,一项为前瞻性队列研究,一项为病例对照研究。三项研究提供了比值比作为效应量指标(两项回顾性横断面研究和一项病例对照研究),一项队列研究报告了风险比作为效应量指标。因此,在排除队列研究的情况下进行荟萃分析。本研究的汇总比值比为1.32(0.80 - 2.18),无统计学意义。由于纳入研究之间存在较大异质性且样本量较小,发现汇总估计值趋向于无效值。
本荟萃分析未发现心房颤动与糖尿病肾病之间存在显著关联。然而,需要更多大样本量的研究来加强两者关联的证据。